Evidence map›Paper›PMID 42562865›Full record

ArticleScientific reports2026

Dual-function MIL-53(Al) incorporated cement composites for strength reinforcement and antibacterial activity.

M Ramadan, Ahmed Radwan, A O Habib, Alaa Mohsen

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

M RamadanChemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt.
Ahmed RadwanChemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt. ahmed.radwan@sci.asu.edu.eg.
A O HabibFaculty of Engineering, Ain Shams University, Cairo, Egypt.
Alaa MohsenFaculty of Engineering, Ain Shams University, Cairo, Egypt. alaa.mohsen@eng.asu.edu.eg.ORCID 0000-0003-2568-7534

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This work presents the development of an antimicrobial cement with enhanced mechanical performance through the incorporation of metal-organic frameworks (MOFs) into the cement matrix. MIL-53(Al) was synthesized in the laboratory and thoroughly characterized using XRD, SEM, HR-TEM, and BET/BJH analyses. Cement pastes were then prepared by introducing MIL-53(Al) at dosages of 0.1, 0.3, 0.5, and 1 wt%. The resulting composites were evaluated in terms of workability, setting time, compressive strength, and antibacterial activity. The findings revealed that the addition of MIL-53(Al) reduces workability while accelerating both initial and final setting times. Mechanical testing demonstrated that a dosage of 0.5 wt% yields the most favorable results, increasing compressive strength by 43.8% after 1 day and 50.0% after 28 days of curing compared to the neat paste. Furthermore, the modified cement exhibited strong antibacterial performance against various strains, including Bacillus subtilis, Staphylococcus aureus, Klebsiella pneumoniae, and Salmonella typhi. Microstructural analyses using XRD and SEM/EDX confirmed that MIL-53(Al) plays a critical role as a filler and nucleation agent, promoting the formation of beneficial hydration products such as tobermorite, hydrogarnet, and strätlingite. These phases enhance matrix densification and load transfer, leading to improved mechanical performance.

Indexed as

Anti-Bacterial AgentsConstruction MaterialsMetal-Organic FrameworksCompressive StrengthMaterials TestingMicrobial Sensitivity TestsAnti-Bacterial AgentsMetal-Organic FrameworksAntibacterial activityFresh and hardened propertiesHospital buildingsMetal-organic frameworksMIL-53(Al)Portland cement

Identifiers

PMID42562865
PMCPMC13448819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.